Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1586 • ACR Convergence 2022
Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study
Satoshi Kubo¹, Yusuke Miyazaki², Koichi Amano³, Kiyoshi Matsui⁴, Hideto Kameda⁵, Yoshino Inoue⁶, Shingo Nakayamada⁶, Takehisa Ogura⁷, Yuko Kaneko⁸, Kunihiro Yamaoka⁹ and Yoshiya Tanaka¹⁰, ¹Department of Advanced Targeted Therapies, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ³Saitama Medical Center, Kawagoe, Japan, ⁴Hyogo College of Medicine, Nishinomiya, Japan, ⁵Toho University, Tokyo, Japan, ⁶First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Toho university, Meguro-ku, Japan, ⁸Keio University, Tokyo, Japan, ⁹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ¹⁰University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (RA).Methods: RA patients who had an inadequate response to methotrexate…
Abstract Number: 1647 • ACR Convergence 2022
Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Matched Cohort Study with Cancer Registry Linkage
Rebecca Brooks¹, Yangyuna Yang¹, Punyasha Roul², Brent Luedders¹, Namrata Singh³, Brian Sauer⁴, Grant Cannon⁵, Joshua Baker⁶, Ted Mikuls⁷ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Retired, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While patients with RA are predisposed to developing lung cancer, prior epidemiologic studies have been limited in their ability to account for potential confounders…
Abstract Number: 1743 • ACR Convergence 2022
Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment
Maria Christofi¹, Ben Mulhearn², Lysette Marshall¹, Megan Sutcliffe¹, Darren Plant¹, Kimme Hyrich¹, Ann Morgan³, Anthony Wilson⁴, John D Isaacs⁵, Soumya Raychaudhuri⁶, Anne Barton¹ and Sebastien Viatte¹, ¹The University of Manchester, Manchester, United Kingdom, ²Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University College Dublin, Dublin, Ireland, ⁵Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex immune mediated disease that affects 1% of the population. Even with modern therapeutic strategies, many patients with RA…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1963 • ACR Convergence 2022
Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
Colleen O'Neill¹ and Veena Patel², ¹Dell Medical School - UTHealth Austin, Austin, TX, ²Dell Medical School - UT Health Austin, Austin, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease (ASCVD) compared to the general population and RA is considered a…
Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Eric Malmhäll-Bah¹, Karin Andersson², Nina Oparina², Sofia Töyrä Silfverswärd³, Malin Erlandsson² and Maria Bokarewa³, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…
Abstract Number: 1998 • ACR Convergence 2022
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
Wendy Walrabenstein¹, Carlijn Wagenaar¹, Marike van der Leeden², Franktien Turkstra¹, Jos Twisk³, Maarten Boers⁴, Henriët van Middendorp⁵, Peter Weijs² and Dirkjan van Schaardenburg², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Epidemiology and Biostatistics, Amsterdam, Netherlands, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁵Leiden University, Leiden, Netherlands
Background/Purpose: Lifestyle factors have been associated with the development and progression of rheumatoid arthritis. Interventions involving whole food plant-based diets (1-3), physical activity (4) or…
Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
Abstract Number: 2217 • ACR Convergence 2022
Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
Amir Razmjou¹, Jennifer Wang¹, Ani Shahbazian¹, Jeffrey Curtis², Dimitrios Pappas³, Joel Kremer⁴ and Christina Charles-Schoeman⁵, ¹UCLA Medical Center, Los Angeles, CA, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
Abstract Number: PP17 • ACR Convergence 2022
Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA
Stephanie Aleite, AiArthritis, St. Louis, MO
Background/Purpose: Patients living with rheumatoid arthritis (RA) often also live with comorbid mental health conditions. Regardless of diagnosed mental health condition, living with a chronic…
Abstract Number: 0021 • ACR Convergence 2022
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…
Abstract Number: 0079 • ACR Convergence 2022
Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
Jeffrey Sparks¹, Hanke Zheng², Taylor Schwartz³, Sang Hee Park², Kris Norris³, Vardhaman Patel⁴, Scott Robinson³, Keith Wittstock⁴, Vadim Khaychuk⁵ and Alison Silverstein³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Bristol Myers Squibb, Princeton, NJ, ³Inovalon Insights, Bowie, MD, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Pennington, MA
Background/Purpose: The objective of this study was to compare persistence among first-line (1L) abatacept, TNF inhibitors (TNFi), and Janus kinase inhibitors (JAKi) in patients with…
Abstract Number: 0198 • ACR Convergence 2022
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
Savia de Souza¹, Andrew Bassett², Ruth Williams² and Elena Nikiphorou³, ¹Independent, London, United Kingdom, ²King's College London, London, United Kingdom, ³Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have relatively recently been licensed to treat inflammatory arthritis (IA); specifically rheumatoid arthritis (RA) and psoriatic arthritis (PsA). They differ…
Abstract Number: 0251 • ACR Convergence 2022
Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
Sara Remuzgo-Martinez¹, Fernanda Genre¹, Veronica Pulito-Cueto², Alfonso Corrales¹, Virgi Portilla¹, Leticia Lera-Gómez¹, Belén Atienza-Mateo¹, María Sebastián Mora-Gil¹, J Gonzalo Ocejo-Vinyals³, Oreste Gualillo⁴, Ricardo Blanco⁵, Ivan Ferraz Amaro⁶, Santos Castañeda⁷, Raquel Lopez Mejias² and Miguel Ángel González-Gay⁸, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²IDIVAL, Santander, Spain, ³Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁷Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁸Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: NFKB1, NKIRAS1, NFATc1, NFATc2 and MTHFR, inflammation and immune response-related genes, predispose to the increased risk of cardiovascular (CV) disease in patients with RA…
Abstract Number: 0267 • ACR Convergence 2022
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
Juan Molina¹, Fernando Sanchez-Alonso², Cristina Bohorquez³, Cesar Diaz-Torne⁴, Carolina Perez-Garcia⁵, Juan Maria Blanco-Madrigal⁶, Paloma Vela-Casampere⁷, José María Älvaro-Gracia¹ and Isabel Castrejon⁸, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, ³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, ⁴Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Department of Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To investigate the occurrence and relative risk of incident malignancy in patients with rheumatic diseases and previous malignancy treated with biologic and targeted synthetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].